Cartesian Therapeutics Inc — Cash Flow (NASDAQ:RNAC) | MetaTrader

Open full chart

Financials

Overview Finanzbericht Statistics Dividends

Quarterly Annual

Cash from operating activities 34.88 M60.38 M31.63 M51.16 M23.67 M 63.23 M Cash from investing activities 741 K17.14 M15 M34.61 M8.74 M 5.32 M Cash from financing activities 14.43 M52.9 M39.22 M13.14 M168.43 M 8.79 M Free cash flow 34.07 M59.3 M30.43 M50.95 M14.58 M 57.56 M

Nachrichten

Cartesian Therapeutics, Inc. (RNAC) Upgraded to Buy: What Does It Mean for the Stock?

Johnson & Johnson Touts Positive Results For Lupus Treatment - Johnson & Johnson (NYSE:JNJ)

2026 Market Outlook: Focus On Pharma For Consistent Returns, Potential Skyrocketing Shares

H.C. Wainwright senkt Kursziel für Cartesian Therapeutics auf 30 US-Dollar

H.C. Wainwright lowers Cartesian Therapeutics stock price target to $30 from $40

Cartesian: Maintaining Buy Rating For Expansion Of Descartes-08 For Myositis (NASDAQ:RNAC)

What's Going On With Cartesian Therapeutics Stock Friday? - Cartesian Therapeutics (NASDAQ:RNAC)

BTIG hebt Kursziel für Cartesian Therapeutics nach Studienerfolg auf 44 US-Dollar an

Cartesian Therapeutics stock price target raised to $44 by BTIG

Nvidia To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Friday - Applied Mat (NASDAQ:AMAT), Gap (NYSE:GAP)

Kyverna Stock: Immune Reset Is Clinically Validated, Market Ignores Potential

Repligen (RGEN) Q3 Earnings and Revenues Surpass Estimates